Neoadjuvant Opdivo Plus Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial Pharmaceutical Investing
Bristol Myers Squibb to Present Data Across Robust Cardiovascular Portfolio at American Heart Association Scientific Sessions 2021 Pharmaceutical Investing
BMY, HEPS, HMLP INVESTOR ALERT BY CLAIMSFILER: Pending Lead Plaintiff Deadline in Class Action Lawsuits Pharmaceutical Investing
AbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on Risankizumab in Psoriatic Arthritis at ACR Convergence 2021 Pharmaceutical Investing
BriaCell Adds Pioneering Immunologist and Cancer Immunotherapy Expert, Suzanne Ostrand-Rosenberg, Ph.D., to its Scientific Advisory Board Biotech Investing
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Bristol-Myers Squibb Company - BMY Pharmaceutical Investing
Bristol Myers Squibb to Highlight More than 80 Abstracts at ASH 2021 Demonstrating Strength of Innovative Therapeutic Platforms Improving Outcomes for a Broad Range of Hematologic Diseases Pharmaceutical Investing
Gilead and Kite Oncology Demonstrate Broad Leadership in Cell Therapy and Expanding Blood Cancer Pipeline Pharmaceutical Investing
AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting Pharmaceutical Investing
